The Erythropoietin Promoter Variant rs1617640 Is Not Associated with Severe Retinopathy of Prematurity, Independent of Treatment with Erythropoietin.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 29731355.
- Also identified by DOI 10.1016/j.jpeds.2018.03.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this case-control study, the erythropoietin (EPO) promoter variant s1617640, linked to high intravitreal EPO concentrations and increased risk of diabetic retinopathy, was not associated with severe retinopathy of prematurity. This finding was observed both in infants with and without recombinant EPO administration.
Medical subject headings
- Erythropoietin
- Promoter Regions, Genetic
- Retinopathy of Prematurity